Previous 10 | Next 10 |
– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Sufficient cash on hand to execute on business plan and reach clinical and regulatory milestones into 2025 ...
Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...
Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisadeȁ...
Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has closed its ...
2024-05-02 08:42:31 ET More on Palisade Bio Palisade Bio stock rallies 50% premarket on colitis drug update Palisade Bio stock rallies nearly 100% on colitis drug analysis Read the full article on Seeking Alpha For further details see: Palisade Bio looks ...
Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has entered int...
2024-05-01 10:41:49 ET DENVER, Colo., May 01, 2024 ( 247marketnews.com )- Brera Holdings (NASDAQ: BREA ), Palisade Bio, Inc. (Nasdaq: PALI ), Getaround (NYSE: GETR ), CytomX Therapeutics, Inc. (Nasdaq: CTMX ), and Predictive Oncology Inc...
A look at the top 10 most actives in the United States Akanda Corp. (AKAN) rose 52.9% to $0.1422 on volume of 108,274,564 shares CytomX Therapeutics Inc. (CTMX) rose 71.8% to $2.8 on volume of 31,588,176 shares Getaround Inc. (GETR) rose 35.9% to $0.2754 on volume of 26,693,135 shares P...
2024-05-01 09:13:26 ET More on Palisade Bio Palisade Bio stock rallies nearly 100% on colitis drug analysis Palisade Bio stock slides 8% amid colitis drug presentation Seeking Alpha’s Quant Rating on Palisade Bio Historical earnings data for Palisade B...
Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year end Carlsbad, CA, May 01, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or th...
News, Short Squeeze, Breakout and More Instantly...
Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track to commence Ph...
Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel...
– Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise and tools in bioinformatics – Candidate PDE4-related biomarkers overlapping with UC pathophysiology have been identified and innovative selection strategy dev...